Dr Reddys bags 180-day marketing exclusivity for Ondansetron tablets

New Delhi, Dec 27 (UNI) Dr Reddys Laboratories Ltd today said it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ondansetron Hydrochloride tablets.

As the first company to file an ANDA containing a paragraph IV certification for this product, the company has been awarded a 180-day period of marketing exclusivity. The company will commence the shipment of this product shortly.

''We are obviously pleased with the final approval of our generic version of Zofran with 180-days of marketing exclusivity. With six product introductions to date in the current year, we are making good progress in building a sustainable base generics business with potential upsides in the US in the medium term,'' company Vice-Chairman and Cheif Executive Officer (CEO) GV Prasad said.

The company's Ondansetron Hydrochloride Tablets are AB-rated generic equivalent of Glaxo SmithKline's Zofran tablets, a product indicated for the prevention of nausea and vomiting associated with cancer treatment.

As per data available with IMS, the brand product has annual sales of about 639 million dollars.

UNI CS KR GC1351